首页 > 最新文献

Progress in Retinal and Eye Research最新文献

英文 中文
Aging, oxidative stress, and cataracts: Therapeutic prospects and translational insights into peroxiredoxin 6 衰老,氧化应激和白内障:治疗前景和对过氧化物还氧蛋白6的翻译见解
IF 14.7 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2026-03-01 Epub Date: 2026-01-21 DOI: 10.1016/j.preteyeres.2026.101444
Eri Kubo , Bhavana Chhunchha , Dhirendra P. Singh
Selenium-independent peroxiredoxin 6 (Prdx6) is a unique member of the peroxiredoxin family, which protects cells from various stressors by regulating reactive oxygen species (ROS) and maintaining survival signaling. As a multifunctional "moonlighting" protein, Prdx6 exhibits glutathione peroxidase (GPx), acidic calcium-independent phospholipase A2, and lysophosphatidylcholine acyltransferase activities, enabling it to reduce ROS. Loss of Prdx6, owing to dysregulation of its transactivator nuclear factor erythroid 2-related factor 2 or aberrant oxidative post-translational modifications from aging or oxidative stress, disrupts cellular homeostasis and triggers inflammatory or non-inflammatory cell death, including apoptosis and pyroptosis. Similar to GPx4, Prdx6 exhibits selenium-independent peroxidase activity and possesses phospholipid hydroperoxide–reducing GPx activity. A novel function of Prdx6 in facilitating selenium utilization was identified recently; that is, it enhances the expression and activity of selenoproteins, especially GPx4, and prevents ferroptosis. Conversely, Prdx6 deficiency reduces selenoprotein levels and promotes ferroptosis. Nevertheless, the molecular mechanisms through which Prdx6 modulates cell death and survival, particularly under aging and oxidative stress conditions contributing to cataractogenesis, remain unclear. In this review, we summarize the current knowledge of Prdx6 regulation and activity during oxidative stress and aging, highlighting its role in inflammatory and non-inflammatory signaling that contributes to eye lens pathology and cataract formation. Additionally, we discuss natural activators and potential therapeutic strategies targeting Prdx6 to extend eye lens health and delay or prevent cataract development. Overall, we conclude that enhancing Prdx6 activity offers a promising strategy to prevent or reverse age-related cataracts.
硒独立过氧化物还蛋白6 (Prdx6)是过氧化物还蛋白家族的独特成员,通过调节活性氧(ROS)和维持生存信号来保护细胞免受各种应激源的影响。作为一种多功能的“兼职”蛋白,Prdx6具有谷胱甘肽过氧化物酶(GPx)、酸性钙非依赖性磷脂酶A2和溶血磷脂酰转移酶活性,使其能够减少ROS。Prdx6的缺失,由于其反激活因子核因子红系2相关因子2的失调或老化或氧化应激引起的异常氧化翻译后修饰,破坏细胞稳态并引发炎症或非炎症性细胞死亡,包括凋亡和焦亡。与GPx4类似,Prdx6具有硒不依赖性过氧化物酶活性,并具有磷脂氢过氧化物还原GPx活性。最近发现了Prdx6在促进硒利用方面的新功能;即增强硒蛋白,尤其是GPx4的表达和活性,防止铁下垂。相反,Prdx6缺乏降低硒蛋白水平,促进铁下垂。然而,Prdx6调节细胞死亡和存活的分子机制,特别是在衰老和氧化应激条件下导致白内障发生的机制尚不清楚。在这篇综述中,我们总结了Prdx6在氧化应激和衰老过程中的调节和活性的现有知识,强调了它在炎症和非炎症信号传导中的作用,这些信号传导有助于晶状体病理和白内障的形成。此外,我们还讨论了针对Prdx6的天然激活剂和潜在的治疗策略,以延长眼晶状体健康,延缓或预防白内障的发展。总之,我们得出结论,增强Prdx6活性为预防或逆转年龄相关性白内障提供了一个有希望的策略。
{"title":"Aging, oxidative stress, and cataracts: Therapeutic prospects and translational insights into peroxiredoxin 6","authors":"Eri Kubo ,&nbsp;Bhavana Chhunchha ,&nbsp;Dhirendra P. Singh","doi":"10.1016/j.preteyeres.2026.101444","DOIUrl":"10.1016/j.preteyeres.2026.101444","url":null,"abstract":"<div><div>Selenium-independent peroxiredoxin 6 (Prdx6) is a unique member of the peroxiredoxin family, which protects cells from various stressors by regulating reactive oxygen species (ROS) and maintaining survival signaling. As a multifunctional \"moonlighting\" protein, Prdx6 exhibits glutathione peroxidase (GPx), acidic calcium-independent phospholipase A2, and lysophosphatidylcholine acyltransferase activities, enabling it to reduce ROS. Loss of Prdx6, owing to dysregulation of its transactivator nuclear factor erythroid 2-related factor 2 or aberrant oxidative post-translational modifications from aging or oxidative stress, disrupts cellular homeostasis and triggers inflammatory or non-inflammatory cell death, including apoptosis and pyroptosis. Similar to GPx4, Prdx6 exhibits selenium-independent peroxidase activity and possesses phospholipid hydroperoxide–reducing GPx activity. A novel function of Prdx6 in facilitating selenium utilization was identified recently; that is, it enhances the expression and activity of selenoproteins, especially GPx4, and prevents ferroptosis. Conversely, Prdx6 deficiency reduces selenoprotein levels and promotes ferroptosis. Nevertheless, the molecular mechanisms through which Prdx6 modulates cell death and survival, particularly under aging and oxidative stress conditions contributing to cataractogenesis, remain unclear. In this review, we summarize the current knowledge of Prdx6 regulation and activity during oxidative stress and aging, highlighting its role in inflammatory and non-inflammatory signaling that contributes to eye lens pathology and cataract formation. Additionally, we discuss natural activators and potential therapeutic strategies targeting Prdx6 to extend eye lens health and delay or prevent cataract development. Overall, we conclude that enhancing Prdx6 activity offers a promising strategy to prevent or reverse age-related cataracts.</div></div>","PeriodicalId":21159,"journal":{"name":"Progress in Retinal and Eye Research","volume":"111 ","pages":"Article 101444"},"PeriodicalIF":14.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146032818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Polypoidal choroidal vasculopathy: In-depth insights and promising future directions 息肉样脉络膜血管病变:深入的见解和有希望的未来方向
IF 14.7 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2026-01-01 Epub Date: 2025-11-11 DOI: 10.1016/j.preteyeres.2025.101414
Zuyi Yang , Wenfei Zhang , Xingwang Gu , Xinyu Zhao , SriniVas R. Sadda , Gemmy Cheung , Adrian Koh , Anat Loewenstein , Bing Li , Chuting Wang , Jiaqi Zhang , Jingyuan Yang , Kehan Jin , Lihui Meng , Lulu Chen , Meiqian He , Minzhen Yuan , Mingyue Luo , Nien Li , Paisan Ruamviboonsuk , Youxin Chen
Polypoidal choroidal vasculopathy (PCV) is an ocular condition predominantly affecting elderly individuals of Asian descent, characterized by the presence of polypoidal lesions and branching neovascular networks in the sub-retinal pigment epithelium (RPE) space. It has garnered increased attention for its potential differences from neovascular age-related macular degeneration. Genetic studies have identified specific genetic markers associated with PCV. Advances in imaging techniques, particularly optical coherence tomography (OCT) and OCT angiography, have significantly enhanced the diagnosis of PCV and our insight into its unique pathogenesis. Treatment strategies for PCV have evolved, with anti-vascular endothelial growth factor (VEGF) monotherapy becoming the primary treatment, and combination therapies including photodynamic therapy showing promising results. Consideration of targets beyond VEGF and the incorporation of artificial intelligence (AI) based analysis strategies may open the door to more personalized, precise, and effective treatments for patients. This review comprehensively discusses the current knowledge and recent advancements in PCV, including its epidemiology, genetics, biomarkers, pathogenesis, diagnosis, and management. It also highlights the need to explore mechanism underlying the higher prevalence of PCV in pigmented races, clarify the roles of pachychoroid and pachydrusen in PCV pathogenesis, and develop animal models that can better recapitulate the disease's pathological features.
息肉样脉络膜血管病变(Polypoidal choroidal vascular pathy, PCV)是一种主要影响亚洲裔老年人的眼部疾病,其特征是视网膜下色素上皮(RPE)间隙存在息肉样病变和分支状新生血管网络。由于其与新生血管性年龄相关性黄斑变性的潜在差异,它已引起越来越多的关注。遗传学研究已经确定了与PCV相关的特定遗传标记。成像技术的进步,特别是光学相干断层扫描(OCT)和OCT血管造影,大大提高了PCV的诊断和我们对其独特发病机制的认识。PCV的治疗策略已经发生了变化,抗血管内皮生长因子(VEGF)单药治疗成为主要治疗方法,包括光动力治疗在内的联合治疗显示出良好的效果。考虑VEGF以外的靶点,并结合基于人工智能(AI)的分析策略,可能为患者提供更个性化、更精确、更有效的治疗方法。本文综述了PCV的流行病学、遗传学、生物标志物、发病机制、诊断和治疗等方面的最新进展。这也强调了探索PCV在色素人种中较高患病率的机制,阐明厚脉络膜和厚脉络膜在PCV发病机制中的作用,并建立能够更好地概括该疾病病理特征的动物模型的必要性。
{"title":"Polypoidal choroidal vasculopathy: In-depth insights and promising future directions","authors":"Zuyi Yang ,&nbsp;Wenfei Zhang ,&nbsp;Xingwang Gu ,&nbsp;Xinyu Zhao ,&nbsp;SriniVas R. Sadda ,&nbsp;Gemmy Cheung ,&nbsp;Adrian Koh ,&nbsp;Anat Loewenstein ,&nbsp;Bing Li ,&nbsp;Chuting Wang ,&nbsp;Jiaqi Zhang ,&nbsp;Jingyuan Yang ,&nbsp;Kehan Jin ,&nbsp;Lihui Meng ,&nbsp;Lulu Chen ,&nbsp;Meiqian He ,&nbsp;Minzhen Yuan ,&nbsp;Mingyue Luo ,&nbsp;Nien Li ,&nbsp;Paisan Ruamviboonsuk ,&nbsp;Youxin Chen","doi":"10.1016/j.preteyeres.2025.101414","DOIUrl":"10.1016/j.preteyeres.2025.101414","url":null,"abstract":"<div><div>Polypoidal choroidal vasculopathy (PCV) is an ocular condition predominantly affecting elderly individuals of Asian descent, characterized by the presence of polypoidal lesions and branching neovascular networks in the sub-retinal pigment epithelium (RPE) space. It has garnered increased attention for its potential differences from neovascular age-related macular degeneration. Genetic studies have identified specific genetic markers associated with PCV. Advances in imaging techniques, particularly optical coherence tomography (OCT) and OCT angiography, have significantly enhanced the diagnosis of PCV and our insight into its unique pathogenesis. Treatment strategies for PCV have evolved, with anti-vascular endothelial growth factor (VEGF) monotherapy becoming the primary treatment, and combination therapies including photodynamic therapy showing promising results. Consideration of targets beyond VEGF and the incorporation of artificial intelligence (AI) based analysis strategies may open the door to more personalized, precise, and effective treatments for patients. This review comprehensively discusses the current knowledge and recent advancements in PCV, including its epidemiology, genetics, biomarkers, pathogenesis, diagnosis, and management. It also highlights the need to explore mechanism underlying the higher prevalence of PCV in pigmented races, clarify the roles of pachychoroid and pachydrusen in PCV pathogenesis, and develop animal models that can better recapitulate the disease's pathological features.</div></div>","PeriodicalId":21159,"journal":{"name":"Progress in Retinal and Eye Research","volume":"110 ","pages":"Article 101414"},"PeriodicalIF":14.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145498695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beyond convolutions and supervised learning with transformers and representation learning for retinal image analysis 超越卷积和监督学习与变压器和表示学习视网膜图像分析
IF 14.7 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2026-01-01 Epub Date: 2025-12-04 DOI: 10.1016/j.preteyeres.2025.101419
Yue Wu , Cecilia S. Lee , Aaron Y. Lee
Retinal image analysis has enjoyed groundbreaking advances in the last ten years due to seismic improvements in image analysis techniques from the field of computer vision. Previous reviews in deep learning and artificial intelligence (AI) (Schmidt-Erfurth et al., 2018; Ting et al., 2019) have either focused on supervised learning, where labels are curated or manually created, or concentrated on the application of AI in specific image modalities and retina diseases (Hormel et al., 2021; Li et al., 2024a (Hormel et al., 2021, Li et al., 2024a)). In this review, we sought to summarize the advances in the field with the shift towards label-free approaches using representational learning and the emergence of vision transformers as alternatives to convolutional neural networks for image analysis. These advances include semi-supervised learning, self-supervised learning and directly led to the advent of foundation models, vision-language models, and multi-modal models.
由于计算机视觉领域的图像分析技术的巨大改进,视网膜图像分析在过去十年中取得了突破性的进展。之前关于深度学习和人工智能(AI)的综述[(Schmidt-Erfurth et al. 2018), (Ting et al. 2019)]要么专注于监督学习,其中标签是精心设计或手动创建的,要么专注于AI在特定图像模式和视网膜疾病中的应用[(Hormel et al. 2021), (Li et al. 2021)。[2024a] (Hormel et al., 2021; Li et al., 2024a)。在这篇综述中,我们试图总结该领域的进展,包括使用表征学习向无标签方法的转变,以及视觉转换器作为图像分析卷积神经网络的替代品的出现。这些进步包括半监督学习、自监督学习,并直接导致了基础模型、视觉语言模型和多模态模型的出现。
{"title":"Beyond convolutions and supervised learning with transformers and representation learning for retinal image analysis","authors":"Yue Wu ,&nbsp;Cecilia S. Lee ,&nbsp;Aaron Y. Lee","doi":"10.1016/j.preteyeres.2025.101419","DOIUrl":"10.1016/j.preteyeres.2025.101419","url":null,"abstract":"<div><div>Retinal image analysis has enjoyed groundbreaking advances in the last ten years due to seismic improvements in image analysis techniques from the field of computer vision. Previous reviews in deep learning and artificial intelligence (AI) (Schmidt-Erfurth et al., 2018; Ting et al., 2019) have either focused on supervised learning, where labels are curated or manually created, or concentrated on the application of AI in specific image modalities and retina diseases (Hormel et al., 2021; Li et al., 2024a (<span><span>Hormel et al., 2021</span></span>, <span><span>Li et al., 2024a</span></span>)). In this review, we sought to summarize the advances in the field with the shift towards label-free approaches using representational learning and the emergence of vision transformers as alternatives to convolutional neural networks for image analysis. These advances include semi-supervised learning, self-supervised learning and directly led to the advent of foundation models, vision-language models, and multi-modal models.</div></div>","PeriodicalId":21159,"journal":{"name":"Progress in Retinal and Eye Research","volume":"110 ","pages":"Article 101419"},"PeriodicalIF":14.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145689326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathological mechanism in Fuchs endothelial corneal dystrophy and myotonic dystrophy type 1: more than meets the eye Fuchs内皮性角膜营养不良和1型肌强直性营养不良的病理机制:大于满足眼睛
IF 14.7 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2026-01-01 Epub Date: 2025-11-22 DOI: 10.1016/j.preteyeres.2025.101418
Elisa Landi , Derick G. Wansink , Vanessa LaPointe , Hans van Bokhoven , Alice E. Davidson , Mor Dickman
Fuchs endothelial corneal dystrophy (FECD) is a heritable disorder distinguished by a progressive degeneration of the corneal endothelium. In its late-onset form, FECD has been associated with a trinucleotide repeat (TNR) expansion (CTG18.1) located in an intronic region of the TCF4 gene, whose frequency is variable among different ancestry groups. Since its discovery, studies investigating CTG18.1-mediated pathogenesis have steadily increased, yet much concerning the unique and tissue-specific clinical features of the disease, as well as its heritable mode of transmission, remain poorly understood. The field of repeat expansion disorders has greatly informed mechanistic understanding of CTG18.1-mediated FECD. In particular, molecular mechanisms underlying myotonic dystrophy type 1, attributed to a CTG expansion in the 3ˈ UTR of the DMPK gene, have considerably informed the FECD field, despite its stark contrast in terms of multisystemic manifestations and variable age at onset. In this work, we critically discuss the non-mutually shared pathogenic parallelisms existing between the pathologies, as well as the unique molecular signatures exhibited by FECD and DM1, speculating on potential research directions for future investigations. Moreover, we discuss the few studies published over the past decade describing the occurrence of FECD in DM1 patients. Here, we debate possible shared molecular signatures that could explain FECD development as a consequence of a non-coding CTG expansion, irrespective of loci (e.g. DMPK or TCF4), and discuss experimental approaches to explain whether these pathologies share toxic mechanisms that arise from these distinct repeat elements.
富克斯内皮性角膜营养不良(FECD)是一种以角膜内皮进行性变性为特征的遗传性疾病。迟发性FECD与位于TCF4基因内含子区域的三核苷酸重复(TNR)扩增(CTG18.1)有关,其频率在不同的祖先群体中是可变的。自发现以来,对ctg18.1介导的发病机制的研究稳步增加,但关于该疾病的独特和组织特异性临床特征及其遗传传播方式的研究仍然知之甚少。重复扩展障碍领域极大地促进了对ctg18.1介导的FECD的机制理解。特别是,1型肌强直性营养不良的分子机制,归因于DMPK基因3个UTR的CTG扩张,已经为FECD领域提供了大量信息,尽管它在多系统表现和发病年龄方面形成鲜明对比。在这项工作中,我们批判性地讨论了病理之间存在的非相互共享的致病相似性,以及FECD和DM1所表现出的独特分子特征,并推测了未来研究的潜在研究方向。此外,我们还讨论了过去十年中发表的关于DM1患者发生FECD的少数研究。在这里,我们讨论了可能共享的分子特征,这些分子特征可以解释非编码CTG扩增的结果,而不管位点(例如DMPK或TCF4),并讨论了实验方法来解释这些病理是否共享由这些不同重复元件产生的毒性机制。
{"title":"Pathological mechanism in Fuchs endothelial corneal dystrophy and myotonic dystrophy type 1: more than meets the eye","authors":"Elisa Landi ,&nbsp;Derick G. Wansink ,&nbsp;Vanessa LaPointe ,&nbsp;Hans van Bokhoven ,&nbsp;Alice E. Davidson ,&nbsp;Mor Dickman","doi":"10.1016/j.preteyeres.2025.101418","DOIUrl":"10.1016/j.preteyeres.2025.101418","url":null,"abstract":"<div><div>Fuchs endothelial corneal dystrophy (FECD) is a heritable disorder distinguished by a progressive degeneration of the corneal endothelium. In its late-onset form, FECD has been associated with a trinucleotide repeat (TNR) expansion (CTG18.1) located in an intronic region of the <em>TCF4</em> gene, whose frequency is variable among different ancestry groups. Since its discovery, studies investigating CTG18.1-mediated pathogenesis have steadily increased, yet much concerning the unique and tissue-specific clinical features of the disease, as well as its heritable mode of transmission, remain poorly understood. The field of repeat expansion disorders has greatly informed mechanistic understanding of CTG18.1-mediated FECD. In particular, molecular mechanisms underlying myotonic dystrophy type 1, attributed to a CTG expansion in the 3ˈ UTR of the <em>DMPK</em> gene, have considerably informed the FECD field, despite its stark contrast in terms of multisystemic manifestations and variable age at onset. In this work, we critically discuss the non-mutually shared pathogenic parallelisms existing between the pathologies, as well as the unique molecular signatures exhibited by FECD and DM1, speculating on potential research directions for future investigations. Moreover, we discuss the few studies published over the past decade describing the occurrence of FECD in DM1 patients. Here, we debate possible shared molecular signatures that could explain FECD development as a consequence of a non-coding CTG expansion, irrespective of loci (e.g. <em>DMPK</em> or <em>TCF4</em>), and discuss experimental approaches to explain whether these pathologies share toxic mechanisms that arise from these distinct repeat elements.</div></div>","PeriodicalId":21159,"journal":{"name":"Progress in Retinal and Eye Research","volume":"110 ","pages":"Article 101418"},"PeriodicalIF":14.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145575514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and effectiveness of vital dyes for intraocular surgery 眼内手术中生命色素的安全性和有效性
IF 14.7 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2026-01-01 Epub Date: 2025-11-01 DOI: 10.1016/j.preteyeres.2025.101412
Mario R. Romano , Mariantonia Ferrara , Peter Szurman , Angelo Spadaro , Hannah J Levis , Andrea Govetto , Tommaso Rossi , Chiara BM. Platania , Kai Januschowski , Claudio Bucolo , Vito Romano
Over the last decade, vital dyes have revolutionized ophthalmic surgery, becoming indispensable tools in many intraocular procedures. These intraocular medical devices enhance visualization, facilitate tissue differentiation and improve surgical precision, ultimately optimizing outcomes. An understanding of their physicochemical properties and staining patterns is crucial for maximizing their benefits and achieving near-histological accuracy. In the recent years, increasing attention has been given to the biocompatibility of intraocular devices to enhance safety and minimise risks. Despite their widespread use, the long-term safety, interactions with intraocular devices, and optimal staining protocols of vital dyes remain insufficiently understood. Addressing these gaps is critical to improving surgical efficacy and patient safety. This review synthesizes recent findings to bridge these knowledge gaps and provide updated clinical insights, offering a comprehensive and detailed analysis of the physicochemical properties, staining mechanisms, and safety profiles of both traditional and newly developed vital dyes. Additionally, it examines how these properties influence surgical efficacy and biocompatibility. We also present an in-depth overview of experimental and clinical studies investigating the potential intraocular toxicity of vital dyes, focusing on crucial and controversial topics, such as surgical risk factors, the interaction between intraocular medical devices and the role of phototoxicity. Drawing on the latest experimental and clinical evidence, we propose updated guidelines to optimise the safe and effective use of vital dyes in intraocular surgery and patients outcomes.
在过去的十年里,重要的染料已经彻底改变了眼科手术,成为许多眼内手术中不可或缺的工具。这些眼内医疗设备增强了可视化,促进了组织分化,提高了手术精度,最终优化了结果。了解其物理化学性质和染色模式对于最大限度地发挥其效益和实现接近组织学的准确性至关重要。近年来,人们越来越关注人工眼罩的生物相容性,以提高安全性和降低风险。尽管它们被广泛使用,但长期安全性、与眼内装置的相互作用以及重要染料的最佳染色方案仍未得到充分的了解。解决这些差距对于提高手术疗效和患者安全至关重要。本综述综合了最近的研究结果,以弥合这些知识差距,并提供最新的临床见解,提供了传统和新开发的重要染料的物理化学特性,染色机制和安全性的全面详细分析。此外,它还检查了这些特性如何影响手术疗效和生物相容性。我们还对重要染料的潜在眼内毒性的实验和临床研究进行了深入的概述,重点介绍了关键和有争议的主题,如手术风险因素、眼内医疗器械之间的相互作用和光毒性的作用。根据最新的实验和临床证据,我们提出了更新的指南,以优化在眼内手术中安全有效地使用重要染料和患者的预后。
{"title":"Safety and effectiveness of vital dyes for intraocular surgery","authors":"Mario R. Romano ,&nbsp;Mariantonia Ferrara ,&nbsp;Peter Szurman ,&nbsp;Angelo Spadaro ,&nbsp;Hannah J Levis ,&nbsp;Andrea Govetto ,&nbsp;Tommaso Rossi ,&nbsp;Chiara BM. Platania ,&nbsp;Kai Januschowski ,&nbsp;Claudio Bucolo ,&nbsp;Vito Romano","doi":"10.1016/j.preteyeres.2025.101412","DOIUrl":"10.1016/j.preteyeres.2025.101412","url":null,"abstract":"<div><div>Over the last decade, vital dyes have revolutionized ophthalmic surgery, becoming indispensable tools in many intraocular procedures. These intraocular medical devices enhance visualization, facilitate tissue differentiation and improve surgical precision, ultimately optimizing outcomes. An understanding of their physicochemical properties and staining patterns is crucial for maximizing their benefits and achieving near-histological accuracy. In the recent years, increasing attention has been given to the biocompatibility of intraocular devices to enhance safety and minimise risks. Despite their widespread use, the long-term safety, interactions with intraocular devices, and optimal staining protocols of vital dyes remain insufficiently understood. Addressing these gaps is critical to improving surgical efficacy and patient safety. This review synthesizes recent findings to bridge these knowledge gaps and provide updated clinical insights, offering a comprehensive and detailed analysis of the physicochemical properties, staining mechanisms, and safety profiles of both traditional and newly developed vital dyes. Additionally, it examines how these properties influence surgical efficacy and biocompatibility. We also present an in-depth overview of experimental and clinical studies investigating the potential intraocular toxicity of vital dyes, focusing on crucial and controversial topics, such as surgical risk factors, the interaction between intraocular medical devices and the role of phototoxicity. Drawing on the latest experimental and clinical evidence, we propose updated guidelines to optimise the safe and effective use of vital dyes in intraocular surgery and patients outcomes.</div></div>","PeriodicalId":21159,"journal":{"name":"Progress in Retinal and Eye Research","volume":"110 ","pages":"Article 101412"},"PeriodicalIF":14.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145412271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surgical management of myopic traction maculopathy; expert perspectives from the myopia society 近视牵引性黄斑病变的外科治疗近视学会专家的观点
IF 14.7 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2026-01-01 Epub Date: 2026-01-03 DOI: 10.1016/j.preteyeres.2025.101434
Hiroyuki Takahashi , Richard F. Spaide , Shu Yen Lee , Yasushi Ikuno , Pei-Ting Lu , Chi-Chun Lai , Yuxin Fang , Chui Ming Gemmy Cheung , Jose M. Ruiz-Moreno , Kyoko Ohno-Matsui
Myopic traction maculopathy (MTM) occurs in approximately 9–34 % of highly myopic eyes and requires surgical treatment to prevent irreversible vision loss due to progression to macular hole (MH) or retinal detachment (RD). While treatment of MTM, which presents with a variety of morphological patterns, shares the common goal of managing the causative tractional tissues on the retina, it is essential to tailor the surgical plan according to the locations of each lesion. Here, we classify MTM into four core lesions: retinoschisis, foveal RD, lamellar MH (LMH), and full-thickness MH (FTMH), and present an algorithm for treatment decision-making. Pars plana vitrectomy (PPV) is a procedure that enables reliable removal of traction-inducing tissues and should be promptly indicated for patients with foveal RD showing progressive vision decline or those with MHRD. Postoperatively, development of macular hole or progression of macular atrophy should be monitored carefully. In recurrent MTM, inadequate membrane peeling is a common cause, requiring wide-field imaging and more intensive intraoperative assessment for residual tissues. Recurrent MTM without FTMH is treated with additional ILM peeling, while recurrence with FTMH is managed surgically using techniques involving ILM flaps, autologous retinal flap, or amniotic membrane transplantation. Macular buckling has also been reported to be effective when used alone or in combination with PPV. Following treatment, long-term follow-up is essential for monitoring both recovery and recurrence. Though further validation through randomized prospective trials is needed, the paradigm for MTM surgery continues to evolve toward preventing persistent vision loss and to optimizing long-term outcomes.
近视牵引力黄斑病变(MTM)发生在大约9 - 34%的高度近视眼睛中,需要手术治疗以防止由于黄斑孔(MH)或视网膜脱离(RD)的进展而导致的不可逆视力丧失。MTM具有多种形态模式,治疗MTM的共同目标是控制视网膜上的致病牵引组织,根据每个病变的位置定制手术计划是至关重要的。在这里,我们将MTM分为四种核心病变:视网膜裂、中央凹RD、板层MH (LMH)和全层MH (FTMH),并提出了一种治疗决策算法。玻璃体切割(PPV)是一种能够可靠地切除牵拉诱导组织的手术,对于出现进行性视力下降的中央凹RD患者或MHRD患者应及时进行手术。术后应仔细观察黄斑裂孔的发展或黄斑萎缩的进展。在复发性MTM中,膜剥离不充分是常见的原因,需要宽视场成像和术中对残余组织进行更深入的评估。复发性MTM无FTMH的治疗采用额外的ILM剥离,而复发的FTMH则采用包括ILM瓣、自体视网膜瓣或羊膜移植在内的手术技术。黄斑屈曲单独使用或与PPV联合使用也有报道。治疗后,长期随访是监测恢复和复发的必要条件。虽然需要通过随机前瞻性试验进一步验证,但MTM手术的范例继续朝着预防持续性视力丧失和优化长期结果的方向发展。
{"title":"Surgical management of myopic traction maculopathy; expert perspectives from the myopia society","authors":"Hiroyuki Takahashi ,&nbsp;Richard F. Spaide ,&nbsp;Shu Yen Lee ,&nbsp;Yasushi Ikuno ,&nbsp;Pei-Ting Lu ,&nbsp;Chi-Chun Lai ,&nbsp;Yuxin Fang ,&nbsp;Chui Ming Gemmy Cheung ,&nbsp;Jose M. Ruiz-Moreno ,&nbsp;Kyoko Ohno-Matsui","doi":"10.1016/j.preteyeres.2025.101434","DOIUrl":"10.1016/j.preteyeres.2025.101434","url":null,"abstract":"<div><div>Myopic traction maculopathy (MTM) occurs in approximately 9–34 % of highly myopic eyes and requires surgical treatment to prevent irreversible vision loss due to progression to macular hole (MH) or retinal detachment (RD). While treatment of MTM, which presents with a variety of morphological patterns, shares the common goal of managing the causative tractional tissues on the retina, it is essential to tailor the surgical plan according to the locations of each lesion. Here, we classify MTM into four core lesions: retinoschisis, foveal RD, lamellar MH (LMH), and full-thickness MH (FTMH), and present an algorithm for treatment decision-making. Pars plana vitrectomy (PPV) is a procedure that enables reliable removal of traction-inducing tissues and should be promptly indicated for patients with foveal RD showing progressive vision decline or those with MHRD. Postoperatively, development of macular hole or progression of macular atrophy should be monitored carefully. In recurrent MTM, inadequate membrane peeling is a common cause, requiring wide-field imaging and more intensive intraoperative assessment for residual tissues. Recurrent MTM without FTMH is treated with additional ILM peeling, while recurrence with FTMH is managed surgically using techniques involving ILM flaps, autologous retinal flap, or amniotic membrane transplantation. Macular buckling has also been reported to be effective when used alone or in combination with PPV. Following treatment, long-term follow-up is essential for monitoring both recovery and recurrence. Though further validation through randomized prospective trials is needed, the paradigm for MTM surgery continues to evolve toward preventing persistent vision loss and to optimizing long-term outcomes.</div></div>","PeriodicalId":21159,"journal":{"name":"Progress in Retinal and Eye Research","volume":"110 ","pages":"Article 101434"},"PeriodicalIF":14.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145893641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Femtosecond lasers in ophthalmology: Mechanisms, clinical breakthroughs, and multidisciplinary frontiers 飞秒激光在眼科:机制、临床突破和多学科前沿
IF 14.7 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2026-01-01 Epub Date: 2025-12-06 DOI: 10.1016/j.preteyeres.2025.101431
Wan-Ping Zhang , Hai-Jun Lv , An-Peng Pan , Wan-Xia Zhang , Xu Shao , Yong-Zheng Qu , An-Song Li , Lin-Hua Chen , Shao-Qun Zeng , A-Yong Yu
Femtosecond laser (FSL) technology has emerged as a transformative force in ophthalmology, offering unprecedented precision in tissue manipulation with minimal collateral thermal and mechanical damage. This comprehensive review traces the evolution of FSL from its fundamental physical principles to its broad spectrum of clinical applications. We examine its roles in refractive surgery, corneal transplantation, presbyopia correction, cataract surgery, glaucoma management, and pterygium excision, as well as recent advancements in intraocular lens customization and nanopatterning. Beyond established clinical use, we explore emerging frontiers where FSL intersects with optogenetics, two-photon photodynamic therapy, and artificial intelligence-augmented optical coherence tomography. Unresolved challenges, including reactive oxygen species-mediated toxicity, cost limitations, and long-term biosafety, are critically discussed. By integrating mechanistic insights, clinical evidence, and translational prospects, this review highlights the potential of FSL to redefine ophthalmic practice through interdisciplinary innovation and to enable the development of personalized, minimally invasive therapeutic strategies.
飞秒激光(FSL)技术已经成为眼科的变革力量,在组织操作方面提供前所未有的精度,同时最小的附带热损伤和机械损伤。这篇全面的综述追溯了FSL从其基本物理原理到广泛临床应用的演变。我们研究了它在屈光手术、角膜移植、老花眼矫正、白内障手术、青光眼治疗和翼状胬肉切除中的作用,以及人工晶状体定制和纳米模式的最新进展。除了既定的临床应用之外,我们还探索了FSL与光遗传学、双光子光动力疗法和人工智能增强光学相干断层扫描交叉的新兴领域。尚未解决的挑战,包括活性氧物种介导的毒性,成本限制和长期生物安全性,进行了批判性的讨论。通过整合机制见解、临床证据和转化前景,本综述强调了FSL通过跨学科创新重新定义眼科实践的潜力,并使个性化、微创治疗策略的发展成为可能。
{"title":"Femtosecond lasers in ophthalmology: Mechanisms, clinical breakthroughs, and multidisciplinary frontiers","authors":"Wan-Ping Zhang ,&nbsp;Hai-Jun Lv ,&nbsp;An-Peng Pan ,&nbsp;Wan-Xia Zhang ,&nbsp;Xu Shao ,&nbsp;Yong-Zheng Qu ,&nbsp;An-Song Li ,&nbsp;Lin-Hua Chen ,&nbsp;Shao-Qun Zeng ,&nbsp;A-Yong Yu","doi":"10.1016/j.preteyeres.2025.101431","DOIUrl":"10.1016/j.preteyeres.2025.101431","url":null,"abstract":"<div><div>Femtosecond laser (FSL) technology has emerged as a transformative force in ophthalmology, offering unprecedented precision in tissue manipulation with minimal collateral thermal and mechanical damage. This comprehensive review traces the evolution of FSL from its fundamental physical principles to its broad spectrum of clinical applications. We examine its roles in refractive surgery, corneal transplantation, presbyopia correction, cataract surgery, glaucoma management, and pterygium excision, as well as recent advancements in intraocular lens customization and nanopatterning. Beyond established clinical use, we explore emerging frontiers where FSL intersects with optogenetics, two-photon photodynamic therapy, and artificial intelligence-augmented optical coherence tomography. Unresolved challenges, including reactive oxygen species-mediated toxicity, cost limitations, and long-term biosafety, are critically discussed. By integrating mechanistic insights, clinical evidence, and translational prospects, this review highlights the potential of FSL to redefine ophthalmic practice through interdisciplinary innovation and to enable the development of personalized, minimally invasive therapeutic strategies.</div></div>","PeriodicalId":21159,"journal":{"name":"Progress in Retinal and Eye Research","volume":"110 ","pages":"Article 101431"},"PeriodicalIF":14.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145689317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glymphatic transport and ocular diseases 淋巴转运与眼部疾病
IF 14.7 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2026-01-01 Epub Date: 2025-12-23 DOI: 10.1016/j.preteyeres.2025.101433
Xiaowei Wang , Christine Delle , Maiken Nedergaard , Peter Wostyn
The high metabolic demand of retinal neurons requires tightly regulated mechanisms to maintain homeostasis and ensure the efficient clearance of metabolic waste and excess water. Recent studies have identified a glymphatic-like system in the rodent eye, and growing evidence supports the existence of a similar pathway in the human eye, facilitating fluid exchange and waste removal. The ocular glymphatic system supports bidirectional flow along the optic nerve - anterograde from the retina and retrograde from the brain.
In this review, we integrate findings from preclinical models and clinically grounded hypotheses to identify key contributors to glymphatic dysfunction in ocular diseases. These include impaired laminar barrier integrity, pathological perivascular space expansion, aquaporin-4 abnormalities, immature vasculature, and pathological immune activation. Glymphatic impairment has been implicated in murine models of glaucoma, diabetic retinopathy, and ocular manifestations of Alzheimer's disease. Additionally, disrupted glymphatic flow is suspected in papilledema, spaceflight associated neuro-ocular syndrome, and Terson syndrome.
We further explore novel associations between glymphatic dysfunction and other blinding disorders such as myopic optic neuropathy, age-related macular degeneration, neuromyelitis optica spectrum disorders, and retinal vasculitis. In delineating these mechanistic links, this review provides a conceptual framework to guide future research in glymphatic contributions to ocular diseases.
视网膜神经元的高代谢需求需要严格调节机制来维持体内平衡,并确保代谢废物和多余水分的有效清除。最近的研究已经在啮齿动物的眼睛中发现了一个类淋巴系统,并且越来越多的证据支持在人眼中存在类似的途径,促进液体交换和废物清除。眼淋巴系统支持沿视神经的双向流动——视网膜的顺行和大脑的逆行。在这篇综述中,我们整合了临床前模型和临床假设的发现,以确定眼病中淋巴功能障碍的关键因素。这些包括层膜屏障完整性受损、病理性血管周围空间扩张、水通道蛋白-4异常、血管不成熟和病理性免疫激活。在青光眼、糖尿病视网膜病变和阿尔茨海默病的眼部表现的小鼠模型中,已经发现了淋巴细胞损伤。此外,在乳头水肿、航天相关的神经-眼综合征和Terson综合征中,怀疑淋巴血流紊乱。我们进一步探讨了淋巴功能障碍与其他致盲疾病(如近视视神经病变、年龄相关性黄斑变性、视神经脊髓炎和视网膜血管炎)之间的新联系。在描述这些机制联系的过程中,本综述提供了一个概念框架,以指导未来关于淋巴细胞在眼部疾病中的作用的研究。
{"title":"Glymphatic transport and ocular diseases","authors":"Xiaowei Wang ,&nbsp;Christine Delle ,&nbsp;Maiken Nedergaard ,&nbsp;Peter Wostyn","doi":"10.1016/j.preteyeres.2025.101433","DOIUrl":"10.1016/j.preteyeres.2025.101433","url":null,"abstract":"<div><div>The high metabolic demand of retinal neurons requires tightly regulated mechanisms to maintain homeostasis and ensure the efficient clearance of metabolic waste and excess water. Recent studies have identified a glymphatic-like system in the rodent eye, and growing evidence supports the existence of a similar pathway in the human eye, facilitating fluid exchange and waste removal. The ocular glymphatic system supports bidirectional flow along the optic nerve - anterograde from the retina and retrograde from the brain.</div><div>In this review, we integrate findings from preclinical models and clinically grounded hypotheses to identify key contributors to glymphatic dysfunction in ocular diseases. These include impaired laminar barrier integrity, pathological perivascular space expansion, aquaporin-4 abnormalities, immature vasculature, and pathological immune activation. Glymphatic impairment has been implicated in murine models of glaucoma, diabetic retinopathy, and ocular manifestations of Alzheimer's disease. Additionally, disrupted glymphatic flow is suspected in papilledema, spaceflight associated neuro-ocular syndrome, and Terson syndrome.</div><div>We further explore novel associations between glymphatic dysfunction and other blinding disorders such as myopic optic neuropathy, age-related macular degeneration, neuromyelitis optica spectrum disorders, and retinal vasculitis. In delineating these mechanistic links, this review provides a conceptual framework to guide future research in glymphatic contributions to ocular diseases.</div></div>","PeriodicalId":21159,"journal":{"name":"Progress in Retinal and Eye Research","volume":"110 ","pages":"Article 101433"},"PeriodicalIF":14.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145822820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quantitative analysis of conjunctival vascular alterations: Applications in ocular and systemic disease detection 结膜血管改变的定量分析:在眼部和全身疾病检测中的应用
IF 14.7 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2026-01-01 Epub Date: 2025-11-17 DOI: 10.1016/j.preteyeres.2025.101416
Xuran Duan , Chaoyu Lei , Chris Hong Long Lim , Jianbin Ding , Jodhbir S. Mehta , Sayan Basu , Luke Johnston , Yujie Ren , Chen Zhao , Victor Koh Teck Chang , Huifang Zhou
The conjunctival blood vessels are the only microcirculatory system on the body surface that can be observed non-invasively. Anatomically interconnected with multiple craniofacial circulatory systems, these vessels can indirectly reflect the blood supply to these areas and the overall state of systemic microcirculation. We synthesize findings from 48 studies spanning 2020–2025. Overall, existing research has found that the conjunctival vascular parameters can change in various diseases such as diabetes, cardiovascular diseases, and autoimmune diseases, and may even precede organic lesions. Recent advancements in conjunctival vessel imaging and analysis technologies have enabled the identification and evaluation of various ocular and systemic diseases based on conjunctival vascular parameters. However, existing studies are limited by insufficient sample sizes, covariate interference, limited disease types, a lack of investigation into the underlying mechanisms of conjunctival vascular changes, and inadequate integration with emerging technologies, such as artificial intelligence. Future research should aim to broaden the scope of investigation, delve deeper into the mechanisms governing conjunctival vascular alterations, and integrate artificial intelligence to establish a solid foundation for the clinical application of conjunctival vascular parameters.
结膜血管是体表唯一可以无创观察到的微循环系统。解剖上,这些血管与多个颅面循环系统相互连接,可以间接反映这些区域的血液供应和全身微循环的整体状态。我们综合了从2020年到2025年的48项研究的结果。总体而言,已有研究发现,结膜血管参数在糖尿病、心血管疾病、自身免疫性疾病等多种疾病中均可发生改变,甚至可能先于器质性病变。最近结膜血管成像和分析技术的进步使得基于结膜血管参数的各种眼部和全身性疾病的识别和评估成为可能。然而,现有的研究受到样本量不足、协变量干扰、疾病类型有限、缺乏对结膜血管变化的潜在机制的调查以及与人工智能等新兴技术的整合不足的限制。未来的研究应扩大研究范围,深入研究结膜血管改变的机制,并结合人工智能,为结膜血管参数的临床应用奠定坚实的基础。
{"title":"Quantitative analysis of conjunctival vascular alterations: Applications in ocular and systemic disease detection","authors":"Xuran Duan ,&nbsp;Chaoyu Lei ,&nbsp;Chris Hong Long Lim ,&nbsp;Jianbin Ding ,&nbsp;Jodhbir S. Mehta ,&nbsp;Sayan Basu ,&nbsp;Luke Johnston ,&nbsp;Yujie Ren ,&nbsp;Chen Zhao ,&nbsp;Victor Koh Teck Chang ,&nbsp;Huifang Zhou","doi":"10.1016/j.preteyeres.2025.101416","DOIUrl":"10.1016/j.preteyeres.2025.101416","url":null,"abstract":"<div><div>The conjunctival blood vessels are the only microcirculatory system on the body surface that can be observed non-invasively. Anatomically interconnected with multiple craniofacial circulatory systems, these vessels can indirectly reflect the blood supply to these areas and the overall state of systemic microcirculation. We synthesize findings from 48 studies spanning 2020–2025. Overall, existing research has found that the conjunctival vascular parameters can change in various diseases such as diabetes, cardiovascular diseases, and autoimmune diseases, and may even precede organic lesions. Recent advancements in conjunctival vessel imaging and analysis technologies have enabled the identification and evaluation of various ocular and systemic diseases based on conjunctival vascular parameters. However, existing studies are limited by insufficient sample sizes, covariate interference, limited disease types, a lack of investigation into the underlying mechanisms of conjunctival vascular changes, and inadequate integration with emerging technologies, such as artificial intelligence. Future research should aim to broaden the scope of investigation, delve deeper into the mechanisms governing conjunctival vascular alterations, and integrate artificial intelligence to establish a solid foundation for the clinical application of conjunctival vascular parameters.</div></div>","PeriodicalId":21159,"journal":{"name":"Progress in Retinal and Eye Research","volume":"110 ","pages":"Article 101416"},"PeriodicalIF":14.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145553612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical histopathology and pathogenesis of macular telangiectasia type 2 2型黄斑毛细血管扩张的临床病理及发病机制。
IF 14.7 1区 医学 Q1 OPHTHALMOLOGY Pub Date : 2026-01-01 Epub Date: 2025-10-20 DOI: 10.1016/j.preteyeres.2025.101401
Dimitrios P. Ntentakis , Anastasia Maria Ntentaki , Eleni Delavogia , Gustavo Sakuno , Victor S.M.C. Corrêa , Nikolaos E. Efstathiou , Mary E. Aronow , Emily Y. Chew , Joan W. Miller , Demetrios G. Vavvas
Macular telangiectasia type 2 (MacTel) is a rare neurodegenerative retinal disease defined by a unique combination of reduced macular pigment, a characteristic angiographic pattern, and a localized clinical presentation. The condition typically affects the temporal perifovea and leads to progressive visual impairment. No definitive treatment exists. Current management is limited to intravitreal anti-vascular endothelial growth factor (VEGF) injections for end-stage neovascular complications and the recently approved Encelto implant (Neurotech Pharmaceuticals, Inc.), which delivers ciliary neurotrophic factor (CNTF) for neuroprotection.
To clarify the still enigmatic pathophysiology of MacTel, we conducted a comprehensive review of all human histopathology reports published in English through December 31, 2024. Findings were systematically evaluated with respect to tissue processing techniques, postmortem fixation times, disease stage at last recorded ophthalmologic evaluation, diagnostic certainty, inclusion of control specimens, and the anatomic origin of analyzed retinal sections. This approach aimed to identify histopathologic features most likely to represent core disease mechanisms.
Each of the features identified as most likely to be pathophysiologically relevant was independently assessed for clinical and histopathologic specificity. These features were then further interpreted in the context of genetic, metabolic, and anatomic associations reported in the literature. Donor demographics, coexisting ocular conditions, and systemic comorbidities were also reviewed to support the development of an integrative hypothesis for MacTel pathogenesis.
Drawing on this synthesis, we propose a histopathology-informed model of disease pathophysiology and outline a provisional timeline for the contribution of key factors to clinical expression. We also review current neuroprotective strategies and provide targeted recommendations for future therapeutic development and histopathologic research. The conceptual framework developed in this work —grounded in rigorous analysis of the most consistent and methodologically validated histopathologic findings, and interpretation of their mechanistic context— may serve as a model for deciphering rare retinal diseases and for generating focused, hypothesis-driven questions to guide future investigation.
2型黄斑毛细血管扩张症(MacTel)是一种罕见的神经退行性视网膜疾病,其特征是黄斑色素减少、血管造影模式和局部临床表现的独特组合。这种情况通常会影响颞窝周围并导致进行性视力障碍。没有明确的治疗方法。目前的治疗仅限于玻璃体内注射抗血管内皮生长因子(VEGF)治疗终末期新生血管并发症,以及最近批准的Encelto植入物(Neurotech Pharmaceuticals, Inc.),该植入物提供睫状神经营养因子(CNTF)用于神经保护。为了阐明仍然是谜的MacTel病理生理学,我们对截至2024年12月31日发表的所有英文人类组织病理学报告进行了全面的回顾。研究人员系统地评估了组织处理技术、死后固定时间、最后记录眼科评估的疾病阶段、诊断确定性、纳入对照标本以及分析视网膜切片的解剖来源。该方法旨在确定最可能代表核心疾病机制的组织病理学特征。每一个特征被确定为最有可能是病理生理学相关的独立评估临床和组织病理学特异性。这些特征随后在文献中报道的遗传、代谢和解剖学关联的背景下进一步解释。供体人口统计、共存的眼部疾病和系统性合并症也被回顾,以支持MacTel发病机制的综合假说的发展。根据这一综合,我们提出了一个组织病理学的疾病病理生理学模型,并概述了关键因素对临床表达的贡献的临时时间表。我们还回顾了当前的神经保护策略,并为未来的治疗发展和组织病理学研究提供了有针对性的建议。在这项工作中开发的概念框架-基于对最一致和方法上验证的组织病理学发现的严格分析,以及对其机制背景的解释-可以作为破解罕见视网膜疾病的模型,并产生集中的,假设驱动的问题,以指导未来的研究。
{"title":"Clinical histopathology and pathogenesis of macular telangiectasia type 2","authors":"Dimitrios P. Ntentakis ,&nbsp;Anastasia Maria Ntentaki ,&nbsp;Eleni Delavogia ,&nbsp;Gustavo Sakuno ,&nbsp;Victor S.M.C. Corrêa ,&nbsp;Nikolaos E. Efstathiou ,&nbsp;Mary E. Aronow ,&nbsp;Emily Y. Chew ,&nbsp;Joan W. Miller ,&nbsp;Demetrios G. Vavvas","doi":"10.1016/j.preteyeres.2025.101401","DOIUrl":"10.1016/j.preteyeres.2025.101401","url":null,"abstract":"<div><div>Macular telangiectasia type 2 (MacTel) is a rare neurodegenerative retinal disease defined by a unique combination of reduced macular pigment, a characteristic angiographic pattern, and a localized clinical presentation. The condition typically affects the temporal perifovea and leads to progressive visual impairment. No definitive treatment exists. Current management is limited to intravitreal anti-vascular endothelial growth factor (VEGF) injections for end-stage neovascular complications and the recently approved Encelto implant (Neurotech Pharmaceuticals, Inc.), which delivers ciliary neurotrophic factor (CNTF) for neuroprotection.</div><div>To clarify the still enigmatic pathophysiology of MacTel, we conducted a comprehensive review of all human histopathology reports published in English through December 31, 2024. Findings were systematically evaluated with respect to tissue processing techniques, postmortem fixation times, disease stage at last recorded ophthalmologic evaluation, diagnostic certainty, inclusion of control specimens, and the anatomic origin of analyzed retinal sections. This approach aimed to identify histopathologic features most likely to represent core disease mechanisms.</div><div>Each of the features identified as most likely to be pathophysiologically relevant was independently assessed for clinical and histopathologic specificity. These features were then further interpreted in the context of genetic, metabolic, and anatomic associations reported in the literature. Donor demographics, coexisting ocular conditions, and systemic comorbidities were also reviewed to support the development of an integrative hypothesis for MacTel pathogenesis.</div><div>Drawing on this synthesis, we propose a histopathology-informed model of disease pathophysiology and outline a provisional timeline for the contribution of key factors to clinical expression. We also review current neuroprotective strategies and provide targeted recommendations for future therapeutic development and histopathologic research. The conceptual framework developed in this work —grounded in rigorous analysis of the most consistent and methodologically validated histopathologic findings, and interpretation of their mechanistic context— may serve as a model for deciphering rare retinal diseases and for generating focused, hypothesis-driven questions to guide future investigation.</div></div>","PeriodicalId":21159,"journal":{"name":"Progress in Retinal and Eye Research","volume":"110 ","pages":"Article 101401"},"PeriodicalIF":14.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145337507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Progress in Retinal and Eye Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1